MannKind Corporation (MNKD)
NASDAQ: MNKD · Real-Time Price · USD
5.03
-0.07 (-1.37%)
At close: Mar 28, 2025, 4:00 PM
5.06
+0.03 (0.65%)
After-hours: Mar 28, 2025, 7:50 PM EDT

Company Description

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of therapeutic products and services for endocrine and orphan lung diseases in the United States.

It offers Afrezza Inhalation Powder, an inhaled insulin used to improve glycemic control in adults with diabetes; the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults; and Tyvaso DPI for the treatment of pulmonary arterial hypertension and pulmonary hypertension.

The company’s product pipeline includes MNKD-101, a nebulized formulation of clofazimine, which is in Phase 3 study, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, which is in phase 1 clinical study, for the treatment of idiopathic pulmonary fibrosis (IPF); MNKD-301, which is in preclinical stage, for cystic fibrosis; and Pediatric Afrezza, which is in phase 3 clinical trial for the treatment of diabetes mellitus.

It has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis.

Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India; and co-promotion agreement with Amphastar for marketing of Baqsimi (glucagon) nasal powder.

MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.

MannKind Corporation
MannKind logo
Country United States
Founded 1991
IPO Date Jul 28, 2004
Industry Biotechnology
Sector Healthcare
Employees 407
CEO Michael Castagna

Contact Details

Address:
1 Casper Street
Danbury, Connecticut 06810
United States
Phone 818 661 5000
Website mannkindcorp.com

Stock Details

Ticker Symbol MNKD
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
CIK Code 0000899460
CUSIP Number 56400P706
ISIN Number US56400P7069
Employer ID 13-3607736
SIC Code 2834

Key Executives

Name Position
Dr. Michael E. Castagna Pharm.D. Chief Executive Officer and Director
Lauren M. Sabella Executive Vice President of Operations
Dr. David B. Thomson J.D., Ph.D. Executive Vice President, General Counsel and Secretary
Dr. Stuart A. Tross Ph.D. Executive Vice President of Human Resources
Christopher B. Prentiss M.B.A. Chief Financial Officer
Sanjay Singh M.B.A. Executive Vice President of Technical Operations
Rosabel Realica Alinaya CPA Vice President of Investor Relations and Treasury
John F. Bedard Senior Vice President of Worldwide Regulatory Affairs
James Patrick McCauley Jr., J.D., M.B.A. Chief Commercial Officer
Dr. Burkhard Blank M.D. Executive Vice President of Research and Development and Chief Medical Officer

Latest SEC Filings

Date Type Title
Feb 26, 2025 S-3ASR Automatic shelf registration statement of securities of well-known seasoned issuers
Feb 26, 2025 10-K Annual Report
Feb 26, 2025 8-K Current Report
Jan 6, 2025 8-K Current Report
Dec 18, 2024 8-K Current Report
Nov 22, 2024 144 Filing
Nov 15, 2024 144 Filing
Nov 7, 2024 10-Q Quarterly Report
Nov 7, 2024 8-K Current Report
Nov 6, 2024 144 Filing